A first-in-human phase 0 clinical study of RNA interference–based spherical nucleic acids in patients with recurrent glioblastoma

A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis

(2020) Teresa Coelho et al.   Orphanet Journal of Rare Diseases

Iron as a Central Player and Promising Target in Cancer Progression

(2019) Michaela Jung et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Longitudinal molecular trajectories of diffuse glioma in adults

(2019) Floris P. Barthel et al.   NATURE

Gene silencing strategies in cancer therapy: An update for drug resistance

(2018) Sanaz Naghizadeh et al.   CURRENT MEDICINAL CHEMISTRY

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

(2017) Roger Stupp et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Lomustine and Bevacizumab in Progressive Glioblastoma

(2017) Wolfgang Wick et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dual bioluminescence and near-infrared fluorescence monitoring to evaluate spherical nucleic acid nanoconjugate activity in vivo

(2017) Timothy L. Sita et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Distribution of Iron Oxide Core-Titanium Dioxide Shell Nanoparticles in VX2 Tumor Bearing Rabbits Introduced by Two Different Delivery Modalities

(2016) Tamer Refaat et al.   Nanomaterials

X-Ray Fluorescence Microscopy for Investigation of Archival Tissues

(2016) T. Paunesku et al.   HEALTH PHYSICS

miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma

(2015) Fotini M. Kouri et al.   GENES & DEVELOPMENT

Clinical experiences with systemically administered siRNA-based therapeutics in cancer

(2015) Jonathan E. Zuckerman et al.   NATURE REVIEWS DRUG DISCOVERY

Recurrent Glioblastomas Reveal Molecular Subtypes Associated with Mechanistic Implications of Drug-Resistance

(2015) So Mee Kwon et al.   PLoS One

An update on RNA interference-mediated gene silencing in cancer therapy

(2014) Yi-Jie Ren et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

First-in-Human Phase I Study of the Liposomal RNA Interference Therapeutic Atu027 in Patients With Advanced Solid Tumors

(2014) Beate Schultheis et al.   JOURNAL OF CLINICAL ONCOLOGY

Probing the inherent stability of siRNA immobilized on nanoparticle constructs

(2014) Stacey N. Barnaby et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA

(2014) J. E. Zuckerman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

Mechanism for the endocytosis of spherical nucleic acid nanoparticle conjugates

(2013) C. H. J. Choi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Spherical Nucleic Acid Nanoparticle Conjugates as an RNAi-Based Therapy for Glioblastoma

(2013) S. A. Jensen et al.   Science Translational Medicine

RNAi-mediated gene silencing in cancer therapy

(2012) Wei-Qiong Yang et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Toward personalized cancer nanomedicine – past, present, and future

(2012) Alexander H. Stegh   Integrative Biology

Spherical Nucleic Acids

(2012) Joshua I. Cutler et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

What drives intense apoptosis resistance and propensity for necrosis in glioblastoma? A role for Bcl2L12 as a multifunctional cell death regulator

(2011) Alexander H. Stegh et al.   CELL CYCLE

Beyond effector caspase inhibition

(2011) Alexander H. Stegh et al.   CELL CYCLE

Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors

(2011) Dirk Strumberg et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor

(2010) A. H. Stegh et al.   GENES & DEVELOPMENT

Impact of bevacizumab chemotherapy on craniotomy wound healing

(2010) Aaron J. Clark et al.   JOURNAL OF NEUROSURGERY

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

(2010) Mark E. Davis et al.   NATURE

Malignant glioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

(2009) R. Stupp et al.   ANNALS OF ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme

(2009) M. H. Cohen et al.   ONCOLOGIST

Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma

(2008) A. H. Stegh et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA